Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency: A systematic review

Senefeld, J.; Klassen, S. A.; Ford, S. K.; Wiggins, C. C.; Bostrom, B. C.; Thompson, M. A.; Baker, S. E.; Nicholson, W. T.; Johnson, P. W.; Carter, R. E.; Henderson, J. P.; Hartman, W. R.; Pirofski, L.-a.; Wright, R. S.; Fairweather, D.; Bruno, K. A.; Paneth, N. S.; Casadevall, A.; Joyner, M. J.

In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2 including among patients with innate or acquired immunodeficiency. However, the association between COVID-19-associated mortality in patients with immunodeficiency and therapeutic use of convalescent plasma is unknown. We review clinical features and treatment protocols of COVID-19 patients with immunodeficiency after treatment with human convalescent plasma. We also discuss the time course and clinical features of recovery. These insights provide evidence for the need to develop a clear treatment protocol for COVID-19 patients with immunodeficiency and support the efficacy of convalescent plasma in patients with primary or secondary immunodeficiency.